{"filings":[{"id":95430,"accession_number":"0001785530-26-000011","cik":1785530,"company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Werewolf Therapeutics Q1 net loss $13.5M; sells JZP898 to Jazz and repays K2 debt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $46.5M as of March 31, 2026, vs $57.1M at Dec 31, 2025.","Net loss of $13.5M for Q1 2026, improved from $18.1M loss in Q1 2025.","R&D expenses $8.2M (down from $13.1M YoY); G&A expenses $5.1M (up from $4.9M).","Entered asset purchase agreement with Jazz Pharmaceuticals for JZP898 (IFNα program); repaid all K2 loan obligations as of May 6, 2026.","Company continues to evaluate strategic alternatives with Piper Sandler; cash runway guidance to be updated."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22505040.795463268,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108510,"accession_number":"0001785530-26-000005","cik":1785530,"company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Werewolf Therapeutics announces strategic alternatives review; Q4 2025 net loss $8.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Engaged Piper Sandler as exclusive financial advisor to explore strategic alternatives including sale, merger, or asset sale.","Cash and equivalents of $57.1M as of Dec 31, 2025; expected to fund operations into Q4 2026.","Q4 2025 net loss $8.4M vs $20.4M in Q4 2024; R&D expenses $6.9M vs $15.7M.","Full year 2025 net loss $60.8M vs $70.5M; R&D expenses $44.8M vs $56.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22505040.795463268,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108509,"accession_number":"0001193125-26-067569","cik":1785530,"company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Werewolf Therapeutics initiates strategic alternatives review, hires Piper Sandler","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Feb 24, 2026: Werewolf (HOWL) announces exploration of strategic alternatives including sale, merger, or licensing.","Hired Piper Sandler & Co. as exclusive financial advisor to assist in the strategic evaluation.","CEO Dan Hicklin cites INDUKINE and INDUCER platforms and clinical-stage candidates as core assets.","No defined timeline; company will not disclose further unless board approves specific action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22505040.795463268,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108508,"accession_number":"0001193125-26-051455","cik":1785530,"company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["2.05","5.02","7.01"],"status":"ready","headline":"Werewolf Therapeutics cuts 64% of workforce; CFO and CMO depart; appoints new principal financial officer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduction in force affecting 64% of workforce; expected completion by Feb 13, 2026.","Estimated one-time charge of ~$4.1 million in Q1 2026 for severance and benefits.","CFO Timothy Trost and CMO Randi Isaacs resign effective Feb 13, 2026; enter 6-month consulting agreements at $250/hour.","Michael Urban named principal financial and accounting officer, effective Feb 13, 2026.","Company evaluating strategic alternatives for WTX-124 and WTX-330 programs; no assurance of transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":22505040.795463268,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108507,"accession_number":"0001193125-26-041305","cik":1785530,"company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Werewolf Therapeutics receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Notice dated Feb 4, 2026: bid price closed below $1.00 for 30 consecutive business days.","Company has 180 calendar days (to Aug 3, 2026) to regain compliance.","To comply, closing bid must be at least $1.00 for 10 consecutive business days.","If initial period fails, may transfer to Nasdaq Capital Market for additional 180 days.","Company monitoring options but no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22505040.795463268,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124951,"accession_number":"0001193125-25-323787","cik":1785530,"company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Werewolf Therapeutics reports 21% ORR for WTX-124 in melanoma, seeks partnerships for INDUKINE programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["WTX-124 monotherapy achieved 21% ORR in heavily pretreated advanced melanoma; 30% ORR in patients not primary resistant to prior immunotherapy.","FDA accepted 18 mg as recommended dose for WTX-124; provided guidance for registration path in post-ICI advanced melanoma.","WTX-330 showed one confirmed partial response in metastatic gall bladder cancer with 45% tumor reduction; favorable tolerability.","Company shifting focus to INDUCER T-cell engager platform; IND filings for WTX-1011 (STEAP1) and WTX-2022 (CDH6) planned mid-2027 pending funding.","Additional funding required to initiate further development of both INDUKINE and INDUCER programs; seeking strategic partners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22505040.795463268,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124950,"accession_number":"0001785530-25-000030","cik":1785530,"company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Werewolf Therapeutics Q3 net loss $16.4M, cash $65.7M; key trial updates due Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $65.7M as of Sept 30, 2025, expected to fund operations into Q4 2026.","Net loss of $16.4M for Q3 2025, comparable to $16.7M in Q3 2024; R&D expense $11.6M, G&A $4.1M.","WTX-124 received Fast Track Designation; interim Phase 1/1b data and End of Phase 1 FDA meeting expected in Q4 2025.","WTX-330 Phase 1b/2 update and development plan expected in Q4 2025.","WTX-1011 (anti-STEAP1 T-cell engager) in IND-enabling studies; target candidate nomination planned by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22505040.795463268,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124949,"accession_number":"0001193125-25-231953","cik":1785530,"company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Board member Dr. Alon Lazarus dies; Werewolf Therapeutics non-compliant with Nasdaq audit committee rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Dr. Alon Lazarus, board member since Aug 2019, passed away on Sep 30, 2025.","His death reduced the Audit Committee to two members, violating Nasdaq Rule 5605(c)(2) requiring three members.","Company notified Nasdaq on Oct 2, 2025; cure period runs until next annual meeting or Sep 30, 2026.","Board plans to appoint an additional independent director to fill the Audit Committee vacancy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":22505040.795463268,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141657,"accession_number":"0001785530-25-000020","cik":1785530,"company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Werewolf Therapeutics Q2 net loss $18M; WTX-124 data on track for Q4 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash $77.6M as of June 30, 2025, providing runway into Q4 2026.","Net loss $18.0M for Q2 2025 vs $17.2M in Q2 2024; R&D $13.1M, G&A $4.4M.","WTX-124 Phase 1/1b interim data expected Q4 2025 in melanoma and renal cell carcinoma.","Planning FDA engagement in H2 2025 to discuss registrational pathway for cutaneous melanoma.","New candidate WTX-1011 (anti-STEAP1 T-cell engager) announced; additional candidate expected by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22505040.795463268,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159547,"accession_number":"0001193125-25-140727","cik":1785530,"company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Werewolf Therapeutics adopts amended bylaws, elects directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted Third Amended and Restated Bylaws effective June 12, 2025, updating stockholder nomination and proposal procedures.","Stockholders elected Briggs Morrison, Michael Sherman, and Anil Singhal as Class I directors for three-year terms ending 2028.","Director vote results: Morrison 19.16M for / 6.33M withheld; Sherman 20.66M for / 4.82M withheld; Singhal 24.58M for / 0.91M withheld.","Ratified Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2025 (33.50M for, 31K against, 84K abstain)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":22505040.795463268,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159546,"accession_number":"0001193125-25-120910","cik":1785530,"company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Werewolf Therapeutics receives Nasdaq deficiency notice for low bid price; has until Nov 10, 2025 to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stock bid price closed below $1.00 for 30 consecutive business days, triggering Nasdaq deficiency notice.","Company has 180 calendar days until November 10, 2025 to regain compliance by closing at $1.00 for 10 consecutive business days.","If not cured, company may seek transfer to Nasdaq Capital Market for additional 180-day period, subject to other listing standards.","Failure to cure could lead to delisting; company plans to monitor bid price and evaluate available options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22505040.795463268,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159545,"accession_number":"0001785530-25-000013","cik":1785530,"company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Werewolf Therapeutics Q1 net loss $18.1M; cash $92M; WTX-124 data/FDA in H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.1M in Q1 2025 vs $16.2M in Q1 2024; R&D spend $13.1M.","Cash and equivalents $92.0M as of March 31, 2025; runway into Q4 2026.","WTX-124 Phase 1/1b on track for interim data and FDA regulatory discussions in H2 2025.","First patient dosed in WTX-330 Phase 1b/2 trial; initial Phase 1 data showed clinical activity and tolerability.","INDUCER T cell engager development candidate expected by end of Q2 2025; PREDATOR masking shown to silence peripheral activity."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22505040.795463268,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177910,"accession_number":"0001785530-25-000006","cik":1785530,"company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Werewolf Therapeutics reports Q4 2024 net loss of $20.4M; cash runway through Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $111.0M at Dec 31, 2024; sufficient to fund operations through Q2 2026.","Net loss $20.4M in Q4 2024 vs $12.0M in Q4 2023; full year net loss $70.5M vs $37.4M.","Collaboration revenue $0 in Q4 2024 as Jazz obligation completed; full year $1.9M vs $19.9M.","WTX-124 monotherapy melanoma expansion arm expected fully enrolled H1 2025; combination arm by end of 2025.","Plan to meet with FDA in H2 2025 for registrational pathways; interim data expected Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22505040.795463268,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177909,"accession_number":"0001193125-25-032804","cik":1785530,"company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Werewolf Therapeutics appoints Anil Singhal to Board; Derek DiRocco to resign at 2025 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Derek DiRocco, M.D. resigns from Board, effective at 2025 annual meeting; no disagreement cited.","Anil Singhal, Ph.D. appointed as Class I director, effective Feb 19, 2025; joins Audit Committee.","Dr. Singhal has >30 years biopharma R&D experience; currently President & CEO of Trishula Therapeutics.","Dr. Singhal receives annual cash comp of $40,000 + $7,500 for Audit Committee; option for 45,000 shares at $1.40, vesting over 3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22505040.795463268,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194628,"accession_number":"0001193125-24-255170","cik":1785530,"company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Werewolf Therapeutics posts updated corporate presentation with no disclosed material changes","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company made an updated corporate presentation available on its website on November 12, 2024.","Presentation furnished as Exhibit 99.1; no specific financial or operational updates detailed in the filing.","No new financial guidance, clinical data, or corporate developments disclosed in the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":22505040.795463268,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194627,"accession_number":"0001785530-24-000033","cik":1785530,"company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Werewolf Therapeutics reports Q3 net loss $16.7M; WTX-330 partial response in melanoma","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.7M for Q3 2024 vs $8.3M in Q3 2023; cash $122.8M, runway through Q2 2026.","WTX-124 monotherapy expansion arms enrolling; initial efficacy data expected H1 2025.","WTX-330 interim data at SITC: 25 patients, 22-fold higher exposure vs rhIL-12, confirmed partial response in melanoma.","New preclinical candidate WTX-921 (IL-10) for inflammatory diseases introduced.","Two WTX-124 patients with confirmed partial responses; one CSCC patient in complete remission >12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22505040.795463268,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210934,"accession_number":"0001785530-24-000026","cik":1785530,"company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Werewolf Therapeutics Q2 2024 net loss $17.2M; positive clinical data for WTX-124 and WTX-330","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.2M in Q2 2024 vs $5.1M in Q2 2023; R&D expenses rose to $15.3M from $9.6M.","Cash and equivalents $135.3M at June 30, 2024; sufficient to fund operations through at least Q1 2026.","WTX-124 monotherapy achieved 3 objective responses, including 1 complete response at 18 mg IV Q2W RDE.","WTX-330 showed 1 unconfirmed partial response in melanoma; therapeutically relevant exposure levels achieved.","Updated WTX-124 combination data and expansion arms expected H2 2024; WTX-330 data in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22505040.795463268,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229386,"accession_number":"0001193125-24-167467","cik":1785530,"company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Werewolf Therapeutics' WTX-330 Phase 1 shows unconfirmed partial response in melanoma; improved tolerability","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["WTX-330 achieved 23-fold higher systemic IL-12 prodrug concentration vs rhIL-12 at 0.024 mg/kg; free IL-12 <1.6% of prodrug (cutoff June 12, 2024).","Unconfirmed partial response in metastatic melanoma patient who had progressed on adjuvant pembrolizumab; confirmatory scan pending.","Two MSS CRC patients achieved stable disease (one for 24 weeks); evidence of CD8+ T and NK cell activation in tumor biopsies.","No Grade 4/5 treatment-related AEs; mild-moderate toxicities (fever, chills, cytopenias) primarily first dose; MTD not established.","Expansion arms open at 0.024 mg/kg for ICI-resistant or ICI-naive patients; additional data expected Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22505040.795463268,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229385,"accession_number":"0001193125-24-152380","cik":1785530,"company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"WTX-124 Phase 1/1b shows 3 objective responses (1 CR) in checkpoint-refractory solid tumors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3 objective responses out of 35 monotherapy-treated patients: 1 confirmed complete response, 2 partial responses.","All responding patients had 100% target lesion regression; responses durable at recommended dose for expansion (RDE).","RDE selected as 18 mg IV every 2 weeks; three expansion arms opened in RCC, melanoma, cutaneous SCC.","WTX-124 + pembrolizumab combination well-tolerated with enhanced T-cell activation in tumors; no new safety signals.","Company plans to engage regulators on potential monotherapy accelerated approval pathway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22505040.795463268,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229384,"accession_number":"0001193125-24-148114","cik":1785530,"company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Werewolf Therapeutics shareholders elect three Class III directors, ratify EY auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Michael Atkins, Luke Evnin, and Alon Lazarus as Class III directors; Atkins 31.6M votes for, Evnin 20.7M, Lazarus 31.5M.","Broker non-votes of 5.1M shares on each director election.","Ratified Ernst & Young as independent auditor for FY2024: 36.7M for, 41.9K against, 2.9K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":22505040.795463268,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229383,"accession_number":"0001785530-24-000018","cik":1785530,"company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Werewolf Therapeutics reports Q1 net loss of $16.2M; cash runway extended to Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.2M in Q1 2024, up from $12.0M loss in Q1 2023; R&D expenses rose to $12.9M.","Cash and equivalents $139.2M at March 31, 2024; new $60M loan from K2 HealthVentures ($30M drawn) extends runway through Q1 2026.","Collaboration revenue from Jazz Pharma fell to $0.7M from $4.5M YoY.","Planned ASCO 2024 presentation of WTX-124 combination dose-escalation data; Q2 interim data for WTX-330 monotherapy.","Preclinical advances: WTX-518 and WTX-712 show tumor regressions in mouse models; IL-10 for IBD presented at AAI."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22505040.795463268,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}